Since the 1960s, marine organisms with robust chemical defense systems have been targeted for “molecular mining,” a method of drug discovery that probes organisms of interest for useful compounds. Chemical agents involved in the defense systems of these organisms often exhibit antibacterial, anti-inflammatory, and chemotherapeutic properties. Capnellene derivatives and their terrestrial counterparts, hirsutanes, demonstrate antibacterial and antitumor properties with pharmacological potential. The diol was also effective against human
leukemia, renal leiomyoblastoma,
colon and
breast cancer cell lines. In the same study, capnellene-8β-ol demonstrated selective toxicity for the renal leiomyoblastoma and
ovarian cancer cell lines, while 3β-acetoxycapnellene-8β,10α,14β-triol was active against leukemia cell lines. The antitumor properties of capnellene derivatives have yet to be explored
in vivo.
Anti-inflammatory properties Capnellene derivatives have recently been identified as possible treatments for
neuropathic pain. Neuropathic pain is characterized by damage to peripheral or central nerves that results in pathological
nociceptive transmission, the neuronal process that responds noxious stimuli. Two capnellene derivatives Δ9,12-capnellene-8β,10α-diol and 8α-acetoxy-Δ9,12-capnellene-10α-ol demonstrate potential as
analgesics capable of attenuating neuropathic pain. These compounds have been shown
in vivo to reduce two proteins that mediate inflammation,
cyclooxygenase-2 (COX-2) and inducible
nitric oxide synthase (iNOS).
In vivo, Δ9,12-capnellene-8β,10α-diol inhibited
hyperalgesia behavior in the mouse model for neuropathic pain in a dose-dependent manner. Additionally, treatment with Δ9,12-capnellene-8β,10α-diol inhibited the up-regulation of immunoreactivity in the mouse model, specifically targeting the production of COX-2. Unlike many
non-steroidal anti-inflammatory drugs, Δ9,12-capnellene-8β,10α-diol is advantageous in its selectivity for the COX isoenzyme COX-2, avoiding many of the gastrointestinal side effects associated with the inhibition of COX-1. This fact would allow for the administration of Δ9,12-capnellene-8β,10α-diol in higher doses, potentially offering significant relief from neuropathic pain. ==References==